| Literature DB >> 35900433 |
Su-Long Wang1, Xi-Lin Liu1, Zhi-Chen Kang2, Yue-Shu Wang1.
Abstract
The effect of platelet-rich plasma on nerve regeneration remains controversial. In this study, we established a rabbit model of sciatic nerve small-gap defects with preserved epineurium and then filled the gaps with platelet-rich plasma. Twenty-eight rabbits were divided into the following groups (7 rabbits/group): model, low-concentration PRP (2.5-3.5-fold concentration of whole blood platelets), medium-concentration PRP (4.5-6.5-fold concentration of whole blood platelets), and high-concentration PRP (7.5-8.5-fold concentration of whole blood platelets). Electrophysiological and histomorphometrical assessments and proteomics analysis were used to evaluate regeneration of the sciatic nerve. Our results showed that platelet-rich plasma containing 4.5-6.5- and 7.5-8.5-fold concentrations of whole blood platelets promoted repair of sciatic nerve injury. Proteomics analysis was performed to investigate the possible mechanism by which platelet-rich plasma promoted nerve regeneration. Proteomics analysis showed that after sciatic nerve injury, platelet-rich plasma increased the expression of integrin subunit β-8 (ITGB8), which participates in angiogenesis, and differentially expressed proteins were mainly enriched in focal adhesion pathways. Additionally, two key proteins, ribosomal protein S27a (RSP27a) and ubiquilin 1 (UBQLN1), which were selected after protein-protein interaction analysis, are involved in the regulation of ubiquitin levels in vivo. These data suggest that platelet-rich plasma promotes peripheral nerve regeneration after sciatic nerve injury by affecting angiogenesis and intracellular ubiquitin levels.Entities:
Keywords: ITGB8; bioinformatic analysis; leukocyte-platelet rich plasma; nerve regeneration; peripheral nerve injury; platelet-rich plasma; proteomic analysis; sciatic nerve injury
Year: 2023 PMID: 35900433 PMCID: PMC9396478 DOI: 10.4103/1673-5374.346461
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 6.058
Protein-protein interaction (PPI) network of all differentially expressed proteins after PRP treatment for sciatic nerve injury
| Protein name | Degree | Uniprot ID | Protein name |
|---|---|---|---|
| 40S ribosomal protein S27a or RPS27A (G1SK22) | 9 connected | G1SKZ3 | Proliferating cell nuclear antigen |
| G1SKM5 | ubiquitin recognition factor | ||
| Q29504 | Ubiquitin-like modifier-activating enzyme 1 | ||
| A0A5F9D391 | Uncharacterized protein | ||
| G1SF30 | Ribosomal protein | ||
| G1U4D7 | 40S ribosomal protein S6 | ||
| G1SI20 | Isocitrate dehydrogenase | ||
| U3KMS5 | COP9 signalosome complex subunit 3 | ||
| G1SFZ8 | Ubiquilin 1 | ||
| Ubiquilin 1 or UBQLN1 (G1SFZ8) | 6 connected | G1SKZ3 | Proliferating cell nuclear antigen |
| G1SKM5 | ubiquitin recognition factor | ||
| G1SK22 | 40S ribosomal protein S27a | ||
| U3KMS5 | COP9 signalosome complex subunit 3 | ||
| A0A5F9D5D4 | Syntaxin 4 | ||
| Q29504 | Ubiquitin-like modifier-activating Enzyme 1 |
The degree is associated with the connections between a specific protein and other proteins. If one protein has more connections to other proteins, the degree of this protein is higher. A higher degree indicates the protein plays a more important role in the PPI network. PRP: Platelet-rich plasma.
Results of MRM verifications for all differentially expressed proteins after PRP treatment of sciatic nerve injury
| Accession | Gene Symbol | Full name | S_ | S_ | C_average | S_average |
|---|---|---|---|---|---|---|
| P26013 |
| Integrin alpha-V:beta-8 | 1.313039394 | 0.019204282 | 285274 | 374576 |
| A0A5F9C4V4 |
| Myosin regulatory light chain 2 | 0.268081266 | 0.002029346 | 62854244 | 16850045.33 |
| A0A5F9CV02 |
| Nuclear factor 1 | 0.720929483 | 0.035980968 | 2512135.667 | 1811072.667 |
| A0A5F9D390 |
| Aldehyde dehydrogenase | 0.574050367 | 0.032825781 | 800414.6667 | 459478.3333 |
| A0A5F9DSK5 |
| Methyl-CpG-binding protein 2 | 0.777293892 | 0.021816219 | 1161047.333 | 902475 |
| G1SD81 |
| Hexokinase | 0.520826636 | 0.04963183 | 61307421.33 | 31930538 |
| G1SFZ8 |
| Ubiquilin 1 | 0.691693251 | 0.003030462 | 4741433.667 | 3279617.667 |
| G1SK22 |
| 40S ribosomal protein S27a | 0.643182234 | 0.001162964 | 359093.6667 | 230962.6667 |
| G1TCQ4 |
| Glucosamine-6-phosphate isomerase | 0.66348163 | 0.024337241 | 2147821.333 | 1425040 |
| G1TED6 |
| Annexin A1 | 0.695565524 | 0.026854872 | 307531498.7 | 213908308 |
| G1U6B2 |
| Delta-aminolevulinic acid dehydratase | 0.578448676 | 0.004303236 | 5921313 | 3425175.667 |
| P29678 |
| Dual specificity mitogen-activated protein kinase 1 | 0.712263071 | 0.002650674 | 228673 | 162875.3333 |
MRM: Multiple reaction mode; PRP: platelet-rich plasma.
| Item | Parameter |
|---|---|
| Database | Uniprot |
| Taxonomy | Oryctolagus cuniculus |
| Enzyme | Trypsin |
| Fixed modifications | Carbamidomethyl (C) |
| Variable modifications | Oxidation (M), acetyl (protein N-term), Met-loss+Acetyl (M), |
| Met-loss (M) | |
| Max missed cleavages | 2 |
| Target false discover rate (Strict) | 0.01 |
| Target false discover rate (Relaxed) | 0.05 |
| Min. peptide length | 6 amino acids |
| Mass tolerance | 10 ppm |
GO and KEGG pathway analysis on protein expression changes after PRPtreatment on sciatic nerve injury
| Category | Term | Count | Gene symbol |
| Fold enrichment |
|---|---|---|---|---|---|
|
| |||||
| GOTERM_B | GO:0006886~intracellular protein transport | 4 |
| 0.03 | 5.47 |
| GOTERM_C | GO:0070062~extracellular exosome | 28 |
| 0.00 | 2.67 |
| GOTERM_M | GO:0005509~calcium ionbinding | 8 |
| 0.01 | 3.29 |
| KEGG_PAT | ocu04510:Focal adhesion | 6 |
| 0.00 | 6.51 |
| HWAY | |||||
| KEGG_PAT | ocu04810:Regulation of actin cytoskeleton | 5 |
| 0.01 | 5.35 |
| HWAY | |||||
| KEGG_PAT | ocu01130:Biosynthesis of antibiotics | 5 |
| 0.02 | 4.82 |
| HWAY | |||||
| KEGG_PAT | ocu00520:Amino sugar and nucleotide sugar metabolism | 3 |
| 0.02 | 14.20 |
| HWAY | |||||
| KEGG_PAT | ocu00280:Valine, leucine and isoleucine degradation | 3 |
| 0.03 | 11.51 |
| HWAY | |||||
| KEGG_PAT | ocu03320:PPAR signaling | 3 |
| 0.04 | 9.27 |
| HWAY pathway | |||||
| KEGG_PAT | ocu01100:Metabolic | 11 |
| 0.04 | 1.90 |
| HWAY pathways |